AL 8697 is a specific and orally active p38α MAPK inhibitor with an IC50 of 6 nM. AL 8697 displays 14-fold greater inhibition of p38α compared to p38β (IC50=82 nM), and 300-fold selectivity for p38α over a panel of 91 kinases. Anti-inflammatory activity.
性状
Solid
IC50 & Target[1][2]
p38α
6 nM (IC50)
p38β
82 nM (IC50)
体内研究(In Vivo)
AL 8697 (1-30 mg/kg; p.o.; once daily for 10 days) dose-dependently decreases the oedema in right and left paws.
Medlife has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model:
Male Wistar rats
Dosage:
1, 3, 10, 30 mg/kg
Administration:
Oral gavage; once daily for 10 days
Result:
Dose-dependently decreased the oedema in right and left paws, causing a larger improvement in the contralateral un-injected paw.